TRF2

TRF2
Name	Telomeric repeat-binding factor 2
Alt	TRF2
Organism	Human
Gene	TERF2
Alias	TERF2L
Location	Chromosome 16

TRF2 TRF2 is a human telomeric protein involved in chromosome end protection and telomere architecture. It participates in telomere capping, shelterin assembly, and influences pathways linked to oncogenesis and aging through interactions with DNA repair factors. TRF2 function is studied across molecular biology, cancer research, and aging fields using diverse cellular and animal models.

Overview

TRF2 was identified in studies that also characterized Elizabeth Blackburn, Carol Greider, and Jack Szostak-related telomere research and later integrated into the shelterin concept alongside POT1, TPP1, TIN2, TRF1, and RAP1 (TERF2IP). It operates at telomeric TTAGGG repeats characterized in vertebrate genomes like Homo sapiens and model organisms such as Mus musculus and Danio rerio. TRF2 interacts with repair proteins studied in contexts including ATM kinase signaling, Mre11 complex function, and PARP1-mediated responses. Seminal work connecting TRF2 to cancer biology has been published by groups affiliated with institutions such as National Institutes of Health and Cold Spring Harbor Laboratory.

Structure and Biochemistry

TRF2 is a member of the Myb-like family of telomere-binding proteins and contains a C-terminal Myb-type helix-turn-helix domain similar to that characterized in proteins studied at European Molecular Biology Laboratory. The protein forms homodimers via a TRFH domain structurally related to domains found in TRF1 and other telomeric proteins. TRF2 associates with shelterin subunits including TIN2 and RAP1 (TERF2IP), and recruits factors such as Apollo (SNM1B) through protein–protein interaction surfaces. X-ray crystallography and cryo-EM analyses from groups at Max Planck Institute and Stanford University have resolved TRF2 domains and interfaces that mediate binding to double-stranded telomeric DNA and higher-order telomeric structures like T-loops described by researchers at Salk Institute.

Function in Telomere Maintenance

TRF2 stabilizes t-loop structures first proposed in models by researchers at Cold Spring Harbor Laboratory and maintains the 3' G-rich overhang identified by labs including University of California, San Diego. By capping telomeres, TRF2 prevents activation of DNA damage responses at chromosome ends and limits access of end-processing enzymes characterized in studies at University of Cambridge and Harvard Medical School. TRF2 cooperates with POT1 and TPP1 to regulate telomerase engagement, a pathway central to discoveries by Shay and Wright and laboratories at University of Texas MD Anderson Cancer Center. TRF2 also influences recombination-based telomere maintenance pathways described in research from Cold Spring Harbor Laboratory and Weizmann Institute of Science.

Role in DNA Damage Response and Genome Stability

Loss or dysfunction of TRF2 triggers DNA damage signaling mediated by ATM kinase and factors in the MRN complex (MRE11-RAD50-NBS1), eliciting responses studied at Memorial Sloan Kettering Cancer Center and Johns Hopkins University. TRF2 modulates non-homologous end joining pathways involving DNA-PKcs and Ku70/80 and affects homologous recombination processes analyzed at Broad Institute. TRF2-mediated repression of ATM prevents telomere fusions and chromosomal instability events cataloged in cancer genomics projects at The Cancer Genome Atlas and clinical studies from Mayo Clinic. TRF2 also interfaces with chromatin remodelers and histone modifiers characterized at Rockefeller University and University of Oxford to maintain telomeric heterochromatin and genome integrity.

Regulation and Post-translational Modifications

TRF2 is regulated transcriptionally by factors studied at European Molecular Biology Laboratory and post-translationally by modifications including phosphorylation by CDK2 and ATM, ubiquitination via E3 ligases characterized at Yale University, SUMOylation studied at University of Pennsylvania, and acetylation processes described at University of Chicago. These modifications alter TRF2 stability, telomeric binding affinity, and interactions with shelterin partners, a regulatory network explored in labs at MIT and UCSF. Proteasomal degradation pathways involving MDM2 and ubiquitin–proteasome system components from research at Cold Spring Harbor Laboratory also influence TRF2 levels under stress conditions.

Pathological Implications and Disease Associations

Aberrant TRF2 expression or function is implicated in oncogenesis, with overexpression linked to tumorigenesis in studies from National Cancer Institute and decreased TRF2 associated with cellular senescence described in aging research at Buck Institute for Research on Aging. TRF2 alterations correlate with genomic instability phenotypes observed in cancers cataloged by International Agency for Research on Cancer and affect responses to chemotherapeutics evaluated in clinical trials at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Germline or somatic perturbations in telomere biology, including TRF2-related pathways, contribute to telomere syndromes investigated at Boston Children's Hospital and predisposition to disorders covered in consortia such as ClinGen.

Experimental Tools and Models

TRF2 is studied using antibodies and dominant-negative constructs developed in laboratories at Addgene and functional genomics approaches using CRISPR/Cas9 platforms from Broad Institute and Sanger Institute. Mouse models with conditional Terf2 alleles created by groups at Harvard Medical School and University of California, San Francisco elucidate roles in development and cancer. Biochemical assays using recombinant TRF2 proteins, single-molecule imaging at facilities like Janelia Research Campus, chromatin immunoprecipitation protocols from Cold Spring Harbor Laboratory, and telomere FISH techniques standardized at Dana-Farber Cancer Institute are routine in TRF2 research.

Category:Telomere-binding proteins